Analysts expect Ionis Pharmaceuticals Inc (NASDAQ:IONS) to post earnings per share of $0.09 for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Ionis Pharmaceuticals’ earnings. The highest EPS estimate is $0.23 and the lowest is ($0.13). Ionis Pharmaceuticals reported earnings of $0.02 per share during the same quarter last year, which indicates a positive year-over-year growth rate of 350%. The firm is scheduled to issue its next earnings report on Tuesday, February 26th.
According to Zacks, analysts expect that Ionis Pharmaceuticals will report full year earnings of ($0.13) per share for the current year, with EPS estimates ranging from ($0.19) to ($0.10). For the next year, analysts anticipate that the company will post earnings of $0.25 per share, with EPS estimates ranging from ($1.24) to $2.71. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that that provide coverage for Ionis Pharmaceuticals.
Ionis Pharmaceuticals (NASDAQ:IONS) last issued its earnings results on Tuesday, November 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.10. Ionis Pharmaceuticals had a negative return on equity of 1.58% and a negative net margin of 7.52%. The business had revenue of $145.40 million during the quarter, compared to analysts’ expectations of $146.77 million. During the same period in the prior year, the firm posted ($0.02) EPS. Ionis Pharmaceuticals’s quarterly revenue was up 22.9% compared to the same quarter last year.
A number of equities analysts have recently issued reports on IONS shares. Stifel Nicolaus dropped their target price on Ionis Pharmaceuticals from $47.00 to $45.00 and set a “hold” rating for the company in a report on Tuesday, August 28th. Morgan Stanley dropped their target price on Ionis Pharmaceuticals from $49.00 to $45.00 and set an “equal weight” rating for the company in a report on Tuesday, August 28th. ValuEngine cut Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 7th. Piper Jaffray Companies set a $50.00 target price on Ionis Pharmaceuticals and gave the stock a “hold” rating in a report on Monday, September 24th. Finally, Zacks Investment Research cut Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 9th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $53.50.
In related news, COO Brett P. Monia sold 34,000 shares of the firm’s stock in a transaction on Friday, November 23rd. The stock was sold at an average price of $55.00, for a total transaction of $1,870,000.00. Following the completion of the sale, the chief operating officer now directly owns 49,841 shares of the company’s stock, valued at approximately $2,741,255. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP C Frank Bennett sold 12,500 shares of the firm’s stock in a transaction on Thursday, November 1st. The shares were sold at an average price of $49.54, for a total value of $619,250.00. Following the sale, the senior vice president now directly owns 31,896 shares of the company’s stock, valued at $1,580,127.84. The disclosure for this sale can be found here. Company insiders own 2.13% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. TRUE Private Wealth Advisors acquired a new stake in Ionis Pharmaceuticals during the 3rd quarter valued at $133,000. Parallel Advisors LLC increased its holdings in Ionis Pharmaceuticals by 195.5% during the 3rd quarter. Parallel Advisors LLC now owns 3,023 shares of the company’s stock valued at $156,000 after purchasing an additional 2,000 shares in the last quarter. Clarus Wealth Advisors increased its holdings in Ionis Pharmaceuticals by 200.0% during the 3rd quarter. Clarus Wealth Advisors now owns 3,600 shares of the company’s stock valued at $186,000 after purchasing an additional 2,400 shares in the last quarter. Cambridge Investment Research Advisors Inc. acquired a new stake in Ionis Pharmaceuticals during the 2nd quarter valued at $212,000. Finally, IFG Advisory LLC acquired a new stake in Ionis Pharmaceuticals during the 3rd quarter valued at $225,000. 85.13% of the stock is owned by hedge funds and other institutional investors.
Shares of IONS opened at $53.12 on Friday. Ionis Pharmaceuticals has a 1 year low of $39.07 and a 1 year high of $59.81. The company has a quick ratio of 7.96, a current ratio of 7.99 and a debt-to-equity ratio of 0.74. The company has a market capitalization of $7.71 billion, a PE ratio of 664.00 and a beta of 2.38.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.
Recommended Story: How Short Selling Works
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.